CREBBP Mutation

CI-VAR-00002764Explore in graph →CIViC 4821

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
CREBBP Mutation	Therapeutic Glucocorticoid	Predictive	D	Supports Resistance	3	submitted	EID8501 Mullighan et al analyzed a cohort of 71 diagnosis-relapse cases and 270 acute leukaemia cases that did not relapse. The authors found that 18.3% of relapse cases had sequence or deletion mutations of … (full text at CIViC) PMID 21390130 · Mullighan et al., 2011 · Open in CIViC	civic
Diffuse Large B-Cell Lymphoma1
CREBBP Mutation	(oncogenic)	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11927 This study showed that CREBBP and EP300 were recurrently mutated in DLBCL PMID 21390126 · Pasqualucci et al., 2011 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.